What is the difference between Angiotensin (1-7) and Teriparatide?

Angiotensin (1-7): Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Teriparatide: Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Is Angiotensin (1-7) FDA approved?

Angiotensin (1-7) is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Teriparatide FDA approved?

Teriparatide is FDA approved (FDA status current as of 2002-11-26). This regulatory status is provided for research and educational context only.

How is Angiotensin (1-7) administered in research settings?

In research settings, Angiotensin (1-7) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Teriparatide administered in research settings?

In research settings, Teriparatide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Angiotensin (1-7) vs Teriparatide

Peptide Comparison

Angiotensin (1-7) vs Teriparatide

Both are Longevity & Cellular peptides.

Angiotensin (1-7)

Ang-(1-7)

LongevityInvestigationalResearch Only

Half-life: ~9–10 sec (rat)

No providers listed yet

Full Angiotensin (1-7) profile →

Teriparatide

Forteo

LongevityFDA ApprovedPrescription

Half-life: ~1 hour

3 providers listed

Full Teriparatide profile →

Bottom line

Teriparatide is FDA-approved, while Angiotensin (1-7) is investigational — the clearest structural difference between them.

Quick Verdict

Angiotensin (1-7)

Half-life

~9–10 sec (rat)

Teriparatide

Half-life

~1 hour

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Teriparatide
Further along in FDA review	Teriparatide
Less frequent dosing (longer half-life)	Angiotensin (1-7)
More provider options (0 vs 3)	Teriparatide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Angiotensin (1-7)

Teriparatide

Mechanism Family

Longevity & Cellular

Half-life

~9–10 sec (rat)

~1 hour

FDA Status

investigational

approved

Admin Routes

subcutaneous, intravenous

subcutaneous

Availability

Research Only

Prescription

Providers

None listed

3 listed

FDA Update

—

Nov 2002

Avail. Notes

—

FDA-approved parathyroid hormone 1-34 analog. Forteo (NDA 021318, Nov 2002) for osteoporosis. Biosimilar Bonsity (NDA 210842, Jan 2020) also approved. Prescription only.

Research Evidence

Angiotensin (1-7)

RCT · 9 key studies · most recent 2026

Teriparatide

Meta-analysis · 4 key studies · most recent 2026

Research Citations

Angiotensin (1-7)

RCT2026 · J Alzheimers Dis

Association between renin angiotensin system and cognitive outcomes over 15 years: The Look AHEAD study.

RCT2024 · Annals of Intensive Care

Angiotensin-(1-7) improves oxygenation in mechanically ventilated COVID-19 patients: a randomized phase 1-2 s…

Case series2026 · Res Sq

Perioperative Angiotensin-(1-7) for Postoperative Cognitive Vulnerability Following Coronary Artery Bypass Su…

Animal2026 · Metabolites

The Effect of Angiotensin (1-7) on Serum Metabolomics in Obese Type 2 Diabetic Mice.

+5 more

Teriparatide

Meta-analysis2026 · J Oral Biosci

The impact of parathyroid hormone supplementation on dental implant osseointegration in osteoporotic subjects…

Meta-analysis2023 · Annals of Internal Medicine

Pharmacological Management of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living…

Cohort2026 · J Orthop

Association between antiosteoporosis medications and risk of sacral fracture after lumbosacral fusion in adul…

Cohort2026 · J Funct Morphol Kinesiol

Biological Augmentation of Reamed Intramedullary Nailing for Aseptic Tibial Shaft Nonunion: An Exploratory Mu…

About Angiotensin (1-7)

Binds Mas receptor (MasR), activating nitric oxide synthase and reducing oxidative stress. Opposes TGF-β and angiotensin II signaling to reduce fibrosis. Enhances insulin sensitivity and provides cardiovascular protection.

Research Areas

cardiovascular protectionanti-fibroticvasodilationinsulin sensitivitykidney protection

About Teriparatide

Recombinant PTH 1-34; when given intermittently, preferentially activates osteoblasts over osteoclasts; increases bone remodeling and net bone formation; stimulates IGF-1 in bone

Research Areas

bone formationbone density increaseosteoporosis reversalfracture risk reduction

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Angiotensin (1-7)

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Teriparatide

Reported (Unverified — Pending Clinical Review)

osteosarcoma risk (2-year limit)Paget's diseaseprior radiation to skeletonhypercalcemia

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Angiotensin (1-7)

Browse directory →

Providers offering

Teriparatide

3 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.